These innovative molecules represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://elainekcop906644.howeweb.com/39793369/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide